About 9Bio Therapeutics

9Bio stands at the confluence of biology, structural engineering, and artificial intelligence, pioneering breakthroughs in oncology therapies that will shape tomorrow’s cancer care.

Our Mission

Engineer previously unimaginable cancer therapies.

Our Values

Innovation

We relentlessly pursue novel solutions, pushing the boundaries of what is possible in biologics.

Ownership

Every member of the 9Bio team takes personal responsibility for their work, driving results with dedication and accountability.

Trust

We believe in fostering an environment of transparency and reliability, ensuring that every stakeholder can count on us.

Community

Beyond our business, we are deeply committed to nurturing a supportive community to create a lasting positive impact.

Meet Our Team

Backed by experience; Advised by recognized experts.

Core Team

Philipe Gobeil, PhD

Philipe Gobeil, PhD

Co-Founder, President & CSO

Philipe, with a PhD from the Western College of Veterinary Medicine at the USask, and a postdoc from Dartmouth, NH, brings over 15 years of expertise in biotech pre-clinical drug development. A decade of this experience is rooted in leadership roles in discovery and pre-clinical drug development projects, several of which have achieved successful commercial out-licensure.

LinkedIn Profile ↗
Henrique de Carvalho, MBA, PMP

Henrique de Carvalho, MBA, PMP

Co-Founder & CEO

Henrique, an MBA graduate from McGill University, brings over 15 years of leadership in biotech product management and commercial operations. He has successfully managed four drug launches at J&J, Sanofi, GSK, and Medicago, including two vaccines that became top-ranked in their categories.

LinkedIn Profile ↗
Jonathan Besna

Jonathan Besna

Sr. Structural Biologist

Jonathan is in his final year of Ph.D. in Biochemistry at Université de Montréal, specializing in protein engineering. With a strong background in structural biology, molecular biology, and bioinformatics, he has developed a comprehensive skill set that spans multiple disciplines. His expertise is validated by various grants, prestigious prizes, and research articles, highlighting significant contributions and extensive knowledge in the field.

LinkedIn Profile ↗
Iris Sun

Iris Sun

R&D Strategy and Intelligence Associate

Iris brings expertise in R&D intelligence and biotech innovation from her roles at Nucleate Dojo, McGill Ventures, and Novateur Ventures. With a strong foundation in research and entrepreneurship, she translates complex scientific and clinical insights into actionable strategies that advance 9Bio’s mission of developing next-generation, conditionally active therapeutics for cancer.

LinkedIn Profile ↗
Jyler Menard

Jyler Menard

Platform Architect

Jyler is a PhD candidate in Physics at Concordia University and an alumnus of the University of Waterloo. He combines expertise in physics, computational biology, and artificial intelligence to accelerate protein-based therapeutic discovery. With deep expertise in molecular dynamics modeling, he brings a unique perspective on protein behavior and conformational dynamics to drive innovation across 9Bio’s platform and predictive modeling capabilities.

LinkedIn Profile ↗
Guilherme Gonçalves

Guilherme Gonçalves

Project Manager

Guilherme holds an MSc in Project Management with a focus on Systems Thinking and a BSc in Computer Science. He brings over 14 years of experience in software development, project leadership, and innovation, with a systems-oriented approach that supports the development of robust and scalable technology platforms.

LinkedIn Profile ↗

Advisors

Dr. Gerald Batist, MD, CM

Dr. Gerald Batist, MD, CM

Advisor

Dr. Gerald Batist is a renowned clinician-scientist with a distinguished career in oncology and molecular pharmacology. He currently serves as the Director of the McGill Centre for Translational Research in Cancer, as well as the Segal Cancer Centre. His contributions to cancer research and treatment have earned him recognition as a Member of the Order of Canada and Knight of the National Order of Quebec.

LinkedIn Profile ↗
Sophie Gobeil, PhD

Sophie Gobeil, PhD

Advisor

Dr. Gobeil is a professor at Université Laval. Her primary research emphasis is on protein structure and visualization, utilizing advanced techniques such as cryo-electron microscopy and X-ray crystallography. Before her tenure at Université Laval, Dr. Gobeil concluded her postdoctoral studies at Duke University, examining the impact of SARS-CoV-2 spike protein mutations on virus infectivity and immune resistance.

LinkedIn Profile ↗
AJ Robert McGray, PhD

AJ Robert McGray, PhD

Advisor

Dr. McGray, Assistant Professor of Oncology and Immunotherapy at Roswell Park Research Center, earned his PhD from McMaster University. After a stint in biotech developing cancer immunotherapies, he returned to Roswell to lead a lab. His current research focuses on bispecific T cell engagers, aiming to amplify anti-tumor immune responses when paired with other advanced treatments.

LinkedIn Profile ↗
Maria I. Marmarinos

Maria I. Marmarinos

Advisor

Ms. Marmarinos is a seasoned negotiator with expertise in licensures, partnerships, and mergers and acquisitions. Before founding Catalyst Group, she held executive roles at NitroMed Inc., Sequella Inc., and Brigham and Women’s Hospital (Boston), and has been an influential faculty member at Harvard Catalyst since 2013.

LinkedIn Profile ↗
Nicolas Petit

Nicolas Petit

Advisor

Nicolas holds an engineering degree in life sciences and a Master’s degree in international management from ESSEC Business School. He has extensive commercial and business development experience spanning Europe, Asia, and North America.

LinkedIn Profile ↗
Sema Burney, MBA, CPA

Sema Burney, MBA, CPA

Advisor

Sema Burney, a distinguished HR leader, is fervently dedicated to diversity and leadership evolution. Possessing an MBA from McGill University and two decades of expertise in HR and accounting, she adeptly bridges HR tactics with concrete business results, fortifying 9Bio’s pledge to inclusivity and organizational excellence.

LinkedIn Profile ↗
Martin Bonenfant, PhD

Martin Bonenfant, PhD

Advisor

Dr. Bonenfant, a Registered Patent Agent with a PhD in Physio-endocrinology from Université Laval, has over 15 years of experience in Legal and Intellectual Property, specializing in the management of patent portfolios and the drafting, negotiation, and approval of contracts and licenses.

LinkedIn Profile ↗
Charles F. Hoyng, PhD

Charles F. Hoyng, PhD

Advisor

Dr. Charles F. Hoyng, formerly a Partner at Latham & Watkins and Morrison & Foerster LLP, specializes in IP and business strategy in life sciences. He has led key biotech transactions, such as GlobeImmune/Gilead and Eli Lilly/United HealthCare. His robust scientific foundation includes a PhD from MIT and roles at Caltech, Texas A&M University, and Genentech.

LinkedIn Profile ↗

Our Partners